Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

BACKGROUND: Docetaxel (D) at the time of starting androgen deprivation therapy (ADT) for metastatic castrate naive prostate cancer shows a clear survival benefit for patients with high-volume (HV) disease. It is unclear whether patients with low-volume (LV) disease benefit from early D. OBJECTIVE: T...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Urol
Main Authors: Gravis, Gwenaelle, Boher, Jean-Marie, Chen, Yu-Hui, Liu, Glenn, Fizazi, Karim, Carducci, Michael A., Oudard, Stephane, Joly, Florence, Jarrard, David M., Soulie, Michel, Eisenberger, Mario J., Habibian, Muriel, Dreicer, Robert, Garcia, Jorge A., Hussain, Maha H.M., Kohli, Manish, Vogelzang, Nicholas J., Picus, Joel, DiPaola, Robert, Sweeney, Christopher
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6010352/
https://ncbi.nlm.nih.gov/pubmed/29475737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2018.02.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados